External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

EAN 2026

We will be contributing to topics related to
-
11:15 AM
Duration 5mins Geneva, Switzerland
Efficacy and Safety of Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results of the FENhance 1 and 2 Studies
Jiwon Oh, Amit Bar-Or, Gavin Giovannoni, Maria Pia Sormani, Martin S. Weber, Sharon Stoll, Jacqueline A. Nicholas, H.-Christian von Büdingen, Marquita Decker-Palmer, Anastasia Loukitcheva, Miriam Triyatni, Nan Hu, John N. Ratchford, Julie Napieralski, Alexandra Goodyear, Ludwig Kappos, Stephen L. Hauser
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:30 AM
Duration 5mins Geneva, Switzerland
Characterizing Patient Profiles Linked to Treatment Persistence in MS: Federated Analysis of Clinical Real-World Data In Different Healthcare Systems
Annalisa Morgan, Bjorn Tackenberg, Erin Longbrake, Gabriele Zilorri, Lawrence Steinman, Markus Elze, Matthias Antonin, Noga Orr, Tina Görbing, Tjalf Ziemssen, Vittorio P Illiano
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:45 AM
Duration 5mins Geneva, Switzerland
Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study
Amit Bar-Or, Jiwon Oh, Gavin Giovannoni, Maria Pia Sormani, Martin S. Weber, Sharon Stoll, Jacqueline A. Nicholas, H.-Christian von Büdingen, Jon Lopez, Louise Roberts, Miriam Triyatni, Qi Qi, John N. Ratchford, Julie Napieralski, Alexandra Goodyear, Stephen L. Hauser, Ludwig Kappos
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Coming soon